Does high-dose atorvastatin reduce major coronary events compared to usual-dose simvastatin in patients with previous myocardial infarction?
In patients with previous MI, high-dose atorvastatin did not significantly reduce major coronary events compared to usual-dose simvastatin, but did reduce nonfatal acute MI without increasing serious adverse reactions.
In this study of patients with previous MI, intensive lowering of LDL-C did not result in a significant reduction in the primary outcome of major coronary events, but did reduce the risk of other composite secondary end points and nonfatal acute MI. There were no differences in cardiovascular or all-cause mortality. Patients with MI may benefit from intensive lowering of LDL-C without an increase in noncardiovascular mortality or other serious adverse reactions.Trial Registration ClinicalTrials.gov Identifier: NCT00159835.
Terje R. Pedersen (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: